Siobhan Ashmore
BACKGROUND
FOCUS AREAS
Siobhan Ashmore brings over 30 years of global experience across the life sciences industry, supporting organizations ranging from startups to multinational pharmaceutical, biotechnology, medical device, dietary supplement, and compounding pharmacies.
New Product Introductions/Submissions, BLA’s, NDA, ANDA, PAI
Quality system implementation/remediation
Digitial systems, global software systems,
Operational excellence
Remediation
Inspection Readiness
Auditing/Inspecting
483, warning letter, consent decree remediation
Digital twin technology
As Partner of ELIQUENT Life Sciences, Siobhan Ashmore advises and supports life science companies navigate complex problems in adherence to global regulations from start-up to commercialization while accelerating innovation and ensuring patient safety.
Siobhan Ashmore brings over 30 years of global experience across the life sciences industry, supporting organizations ranging from startups to multinational pharmaceutical, biotechnology, medical device, dietary supplement, and compounding pharmacies.
Having worked with leading life science companies including Pfizer, Amgen, Johnson & Johnson, Abbott, Ro Healthcare, and many others. Siobhan has extensive expertise in regulatory strategy, new product submissions, CMC, quality systems, manufacturing processes, formulation development, and global regulatory compliance. Her experience spans North America, Europe, and the Asia-Pacific region, enabling her to effectively navigate diverse regulatory environments and complex compliance challenges.
Throughout her career, Siobhan has successfully guided organizations through regulatory inspections, inspection readiness programs, FDA Form 483 observation responses, Warning Letter remediation, and Consent Decree compliance initiatives. She is widely recognized for her ability to strengthen quality systems, mitigate regulatory risk, and establish sustainable compliance frameworks across global operations.
Siobhan spent 10 years as a Global Auditor with Pfizer, where she developed deep expertise in quality assurance, auditing, and regulatory oversight within complex international organizations. She has also served on behalf of State Boards of Pharmacy as both a 503A and 503B Pharmacy Inspector, providing valuable governance, compliance, and regulatory enforcement expertise within the compounding pharmacy sector.
In addition to her regulatory and quality leadership experience, Siobhan serves as a trusted board-level advisor on risk management, compliance, corporate governance, and scalable growth strategies for emerging biotechnology and life sciences companies. She works closely with startup organizations to support enterprise value creation, operational scaling, investor readiness, digital transformation initiatives, AI governance frameworks, and global regulatory strategies that strengthen organizational resilience and build investor confidence.
Her broad industry experience, combined with a comprehensive understanding of regulatory requirements, quality systems, operational excellence, and strategic growth, enables her to help organizations achieve compliance objectives, enhance performance, accelerate innovation, and successfully navigate evolving global regulatory expectations.
-
EDUCATION:
Bachelor of Science -Chemistry
• BSc – Analytical Chemistry, Atlantic Technological University,
Ireland
• National Certificate in Management, Australia
• Qualified Person (QP) – Masters in Pharmaceutical Science (In Progress / On Hold)CERTIFICATIONS:
• Lead Auditor Training EU (1999)
• Global Corporate Auditor (Pfizer, 2002)
• Global Gallup Strengths Counselor (2023)ASSOCIATIONS:
• Board Member – SOPPhC (Society of Pharmaceutical & Healthcare Compliance) (2025 -Present)
• Board Member – ASQ Board Member – Auditing
• Board Facilitator (5 Year Strategic Plan Build-out) ISPE Strategic Leader & Board
Facilitator (5-Year Strategic Plan) Washington DC. (2023)
• PDA Guidance Document Contributor – Remote GMP/GDP Inspection Guidance
• Speaker – KENX, ISPE, University of Miami
• Author – Tablets & Capsules Magazine -
Executive Summary of Expertise:
Siobhan Ashmore is a senior life sciences executive and regulatory compliance leader with more than 30 years of global experience across pharmaceutical, biotechnology, medical device, CDMO, dietary supplement, and compounding pharmacy sectors. Her expertise spans quality and regulatory leadership, global compliance, inspection readiness, manufacturing operations, digital transformation, and strategic business growth across North America, Europe, and Asia-Pacific.
Core Areas of Expertise
Global Quality & Regulatory Compliance
FDA, EMA, MHRA, TGA, and international regulatory submissions
Chemistry, Manufacturing & Controls (CMC)
Inspection Readiness and Regulatory Remediation
FDA Form 483, Warning Letter, Consent Decree, and PAI remediation
Quality Management Systems (QMS) design and implementation
503A and 503B Compounding Pharmacy Compliance
Data Integrity and Computer System Validation (CSV)
21 CFR Part 11, EU Annex 11, GAMP 5 compliance
Sterile Manufacturing and Aseptic Processing
Technology Transfer and New Product Introduction (NPI)
Supplier Qualification and Global Auditing Programs
Digital Transformation and AI Governance
Risk Management and ICH Q9 Implementation
Mergers, Acquisitions, and Post-Acquisition Integration
Business Development and Strategic Growth
Board Advisory Services and Investor Readiness
Enterprise Value Creation and Operational Scaling
Key Leadership Positions HeldRegional Business Development Lead / Solutions Delivery Lead
Medical Engineering Consultants (2025–Present)
Leads Medical Device and Pharmaceutical business growth.
Responsible for commercial strategy, client acquisition, consulting delivery, and operational infrastructure.
Generates approximately $7M in annual revenue.
Provides expert regulatory and remediation consulting for FDA-regulated organizations.
Quality & Regulatory ConsultantMerck Animal Health (2024–2025)
Led global QA/RA transformation initiatives.
Directed inspection readiness, risk management, and quality systems remediation.
Supported global product launch and manufacturing site evaluations.
Lead Inspector / Regulatory AdvisorGates Healthcare Consultancy (2023–2024)
Conducted State Board of Pharmacy inspections for 503A and 503B facilities.
Led regulatory readiness, DEA compliance programs, and compounding facility development.
Vice President, Quality & Regulatory (Consultant)Meds LLC / BlueChew (2022–2023)
Built enterprise quality and regulatory infrastructure.
Led ANDA submissions, facility design, validation programs, and strategic planning.
Director of Compounding QualityRo Healthcare (2021–2022)
Designed and launched a 503A/OTC manufacturing facility.
Led quality systems implementation and regulatory readiness.
Advised executive leadership on growth and expansion strategies.
Principal Consultant – Global CSV & Data IntegrityAmgen (via CAI Commissioning Agents) (2019–2022)
Directed global computer system validation and data integrity programs.
Oversaw compliance across 170+ enterprise systems.
Led supplier qualification, Track & Trace, and digital transformation initiatives.
Quality & Regulatory ConsultantEmergent BioSolutions / Johnson & Johnson Vaccine Program (2021–2022)
Led FDA 483 remediation efforts.
Rebuilt aseptic processing, validation, and contamination control systems.
Vice President, Quality & RegulatoryMedical Engineering Consultants (2018–2019)
Established and scaled pharmaceutical consulting operations in the United States.
Led business development and global compliance projects.
Founder / Lead Auditor & AdvisorLife Science Solutions LLC (2009–Present)
Trusted advisor to leading pharmaceutical, biotech, CDMO, and compounding organizations worldwide.
Delivered more than 50 global audits and remediation programs.
Led inspection readiness, quality transformation, and compliance initiatives.
FDA Remediation ConsultantNoven Pharmaceuticals (2017–2018)
Directed FDA inspection readiness and remediation activities.
Led QMS recovery, supplier qualification remediation, and LIMS validation projects.
Pre-Approval Inspection DirectorPfizer Ireland (2008–2009)
Led FDA Pre-Approval Inspections (IND and ANDA submissions).
Supported development of Pfizer’s vaccine manufacturing facility in Dublin.
Global Compliance Director / Site Quality Manager / Site Technical ManagerPfizer Australia (1999–2008)
Managed global quality and regulatory operations.
Led CMC submissions and worldwide compliance programs.
Managed teams of up to 70 personnel.
Served as Pfizer Global Lead Auditor and Regulatory Trainer.
Quality Assurance ManagerMedNova (Acquired by Abbott and Johnson & Johnson) (1997–1999)
Built EN46001/46002-compliant quality systems.
Supported development of innovative carotid artery stent technology.
Led FDA 510(k) and EU regulatory submissions.
Quality EngineerDeRoyal Medical (1996–1997)
Managed supplier qualification programs.
Led CE marking compliance and internal/external audits.
Career Highlights
30+ years of global leadership experience in life sciences.
Former Pfizer Global Lead Auditor with 10 years auditing experience.
State Board of Pharmacy Inspector for both 503A and 503B facilities.
Led 50+ global audits, remediation programs, and inspection readiness engagements.
Managed global teams across pharmaceutical, biotech, medical device, CDMO, and compounding sectors.
Extensive expertise in FDA, EMA, MHRA, TGA, DEA, NABP, and international regulatory requirements.
Trusted board-level advisor supporting startup biotech and life sciences companies in governance, investor readiness, AI governance, digital transformation, and scalable growth strategies.
Ready for regulatory clarity? Contact Us.
(* Indicated fields are mandatory.)